In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow.

Autoimmune rheumatic diseases (ARDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic ...

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...

Patients with and without preexisting autoimmune or inflammatory disease show similar safety and cancer outcomes after chimeric antigen receptor (CAR) T-cell therapy for cancer. Researchers conducted ...

The U.S. Food & Drug Administration (FDA) recently removed its Risk Evaluation and Mitigation Strategies (REMS) designation from CAR T immunotherapies. REMS is occasionally applied to drugs with ...

Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...

NEW YORK (WRGB) — The Food and Drug Administration has announced new guidelines that will make CAR T-cell therapy more accessible to cancer patients. This development is being hailed as a potential ...

Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll. Mark Daniels, an 83-year-old veteran, pilot and gym ...

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...